Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Open-label Study to Assess the Safety, Tolerability, and Dosing Regimen of Antithrombotic Heparin Proteoglycan Mimetic APAC in Patients With Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia Undergoing Endovascular Revascularization

NCT07352800 is registered in ClinicalTrials.gov with Aplagon Oy as lead sponsor.

NCT NCT07352800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07352800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Open-label Study to Assess the Safety, Tolerability, and Dosing Regimen of Antithrombotic Heparin Proteoglycan Mimetic APAC in Patients With Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia Undergoing Endovascular Revascularization
Lead sponsor
Aplagon Oy
Phase
Phase 2
Overall status
Recruiting
Start date
January 29, 2026
Completion date
June 30, 2027
Enrollment
42 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic limb-threatening ischemia, peripheral arterial occlusive disease